Investor Presentation
141
Investor presentation First six months of 2022
Resource allocation in Novo Nordisk is guided by investing in
future growth while delivering attractive shareholder returns
Corporate strategy guides resource allocation
Expected primary sales growth drivers towards 2030
Diabetes care
Strengthen leadership by
offering innovative medicines
and driving patient
outcomes
Rare disease
Secure a leading position
by leveraging full portfolio
and expanding into
adjacent areas
Novo
Nordisk
Way
Driving change to
defeat diabetes
and other serious
chronic diseases
Sustainable business
Ge
PR
Obesity care
Strengthen treatment options
through market development
and by offering innovative
medicines and driving patient
outcomes
Other serious
Waves of growth
chronic diseases
Establish presence by
building competitive pipeline
and scientific leadership
GLP-1
Diabetes
Focus on driving sustained sales growth
•
•
Commercial investments in growth markets and products
R&D investments in future growth assets
R&D: Research and Development; OSCD: Other serious chronic diseases; RNA: Ribonucleic acid
Obesity
care
Novo NordiskⓇ
ILLUSTRATIVE
Research technology
OSCD
Rare disease
platforms
2020
2025
2030View entire presentation